APA (7th ed.) Citation

MA, D., G, B., BJP, H., A, K., A, A., A, C., . . . M, D. (2023). A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies. Clinical cancer research : an official journal of the American Association for Cancer Research, 29(4), 711. https://doi.org/10.1158/1078-0432.CCR-22-1284

Chicago Style (17th ed.) Citation

MA, Dawson, et al. "A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 29, no. 4 (2023): 711. https://doi.org/10.1158/1078-0432.CCR-22-1284.

MLA (9th ed.) Citation

MA, Dawson, et al. "A Phase I/II Open-Label Study of Molibresib for the Treatment of Relapsed/Refractory Hematologic Malignancies." Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, vol. 29, no. 4, 2023, p. 711, https://doi.org/10.1158/1078-0432.CCR-22-1284.